EICHORPublic-registry trials using SL-325 that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
SL-325 appears in 1 registered trial Eichor's radar has found, sponsored by Shattuck Labs, Inc., the most recent registered as Phase 2, with a planned enrollment of 232. Registered timeline: 2026–2028. The registry holds 2,063 registered studies for Crohn's Disease.
| Trial | Sponsor | Condition | Phase | Sites |
| A Phase 2 Study of SL-325 in Crohn's Disease Patients | Shattuck Labs, Inc. | Crohn's Disease | PHASE2 | 0 |
| Status | Not Yet Recruiting · planned start 2026-10 |
| Primary completion | 2028-07 |
| Enrollment target | 232 participants |
| Design | Randomized · Parallel · Phase 2 · 4 arms |
| Who it enrolls | All sexes · 18 Years and older — full criteria are on the study record |
| Locations | not yet posted — the record updates as sites are announced |
All fields verbatim from the ClinicalTrials.gov record for NCT07753850.
| First registered study | September 2025 — NCT07158437 (Shattuck Labs, Inc.) |
| Registered studies matching this name | 2 all-time · 0 currently recruiting |
Source: ClinicalTrials.gov, the public trial registry.
The public registry holds 2,063 registered studies for Crohn's Disease. Compounds appearing across the 200 most recently updated registry entries:
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Trialed alongside
← Eichor home · All tracked trials · Crohn's Disease studies · Weekly briefs
